NASDAQ:NXTC NextCure Q4 2024 Earnings Results & Report $6.40 +0.17 (+2.73%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$6.48 +0.07 (+1.17%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. NextCure missed analyst earnings expectations in its Q4 2024 results, released March 6, 2025. The company reported EPS of -$4.92 versus the -$4.08 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 6, 2025TimeAfter Market ClosesConference Call4:00 PM ET NextCure EPS ResultsActual EPS-$4.92Consensus EPS -$4.08Beat/MissMissed by -$0.84One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersNextCure Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) NextCure Q4 2024 Earnings FAQ Did NextCure beat earnings estimates for Q4 2024? NextCure (NASDAQ:NXTC) reported earnings of -$4.92 per share for Q4 2024, missing the consensus estimate of -$4.08. The report was announced on Thursday, March 6, 2025. NextCure Earnings HeadlinesNextCure (NASDAQ:NXTC) Rating Lowered to Sell at Wall Street ZenNovember 14 at 1:48 AM | americanbankingnews.comNextCure (NASDAQ:NXTC) Share Price Breaks Below Fifty Day Moving Average Following Weak EarningsNovember 12 at 2:01 AM | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 15 at 1:00 AM | Weiss Ratings (Ad)NextCure Provides Business Update and Reports Third Quarter 2026 Financial ResultsNovember 10, 2026 | globenewswire.comNextCure CMO Departs Amid Pending Avere MergerOctober 30, 2026 | tipranks.comNextCure Faces Court Review of Reverse Stock SplitSeptember 28, 2026 | theglobeandmail.comSee More NextCure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email. Email Address About NextCureNextCure (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company researches immunomedicines designed to influence how immune cells recognize and respond to tumors; it does not market approved commercial products. Its discovery work has included antibody-based and small-molecule candidates aimed at immune-related targets such as Siglec-15, LAIR-1 and CBL-B. NextCure has used its FIND-IT platform to identify and investigate potential therapeutic targets and drug candidates. Founded in 2015, NextCure is based in Beltsville, Maryland. Its work is centered on oncology research and clinical development.View NextCure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
